136 related articles for article (PubMed ID: 31504796)
1. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.
Pasqualetti F; Restante G; Gonnelli A; Rofi E; Molinari A; Crucitta S; Paiar F; Rudà R; Danesi R; Soffietti R; Del Re M
Neuro Oncol; 2019 Dec; 21(12):1610-1611. PubMed ID: 31504796
[No Abstract] [Full Text] [Related]
2. Efficacy of Dabrafenib for three children with brainstem BRAF
Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
[TBL] [Abstract][Full Text] [Related]
3. Recurrent ganglioglioma in adults treated with BRAF inhibitors.
Chamberlain MC
CNS Oncol; 2016; 5(1):27-9. PubMed ID: 26680369
[TBL] [Abstract][Full Text] [Related]
4. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
[TBL] [Abstract][Full Text] [Related]
5. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma.
Shih KC; Shastry M; Williams JT; Jelsma PF; Abram SR; Ayyanar K; Burris HA; Infante JR
J Clin Oncol; 2014 Oct; 32(29):e98-e100. PubMed ID: 24516030
[No Abstract] [Full Text] [Related]
7. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
Bourque MS; Salek M; Sabin ND; Canale M; Upadhyaya SA
Pediatr Blood Cancer; 2021 Apr; 68(4):e28814. PubMed ID: 33211390
[No Abstract] [Full Text] [Related]
8. Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.
Meletath SK; Pavlick D; Brennan T; Hamilton R; Chmielecki J; Elvin JA; Palma N; Ross JS; Miller VA; Stephens PJ; Snipes G; Rajaram V; Ali SM; Melguizo-Gavilanes I
J Natl Compr Canc Netw; 2016 Nov; 14(11):1345-1350. PubMed ID: 27799506
[TBL] [Abstract][Full Text] [Related]
9. Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.
Yau WH; Ameratunga M
J Clin Pharm Ther; 2020 Oct; 45(5):1172-1174. PubMed ID: 31985841
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
Gibney GT; Zager JS
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib and cobimetinib overcome resistance to vemurafenib in
Touat M; Gratieux J; Condette Auliac S; Sejean K; Aldea S; Savatovsky J; Perkins G; Blons H; Ligon KL; Idbaih A; Hollebecque A; Gimenez-Roqueplo AP; Laurent-Puig P; Sanson M; Villa C; Di Stefano AL
Neurology; 2018 Sep; 91(11):523-525. PubMed ID: 30120137
[No Abstract] [Full Text] [Related]
13. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
Brown NF; Carter T; Mulholland P
CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
[TBL] [Abstract][Full Text] [Related]
14. Dabrafenib Effective in Pediatric Glioma.
Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib.
Kainthla R; Kim KB; Falchook GS
Recent Results Cancer Res; 2014; 201():227-40. PubMed ID: 24756796
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
17. A Secondary Mutation in
Wang J; Yao Z; Jonsson P; Allen AN; Qin ACR; Uddin S; Dunkel IJ; Petriccione M; Manova K; Haque S; Rosenblum MK; Pisapia DJ; Rosen N; Taylor BS; Pratilas CA
Cancer Discov; 2018 Sep; 8(9):1130-1141. PubMed ID: 29880583
[TBL] [Abstract][Full Text] [Related]
18. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
del Bufalo F; Carai A; Figà-Talamanca L; Pettorini B; Mallucci C; Giangaspero F; Antonelli M; Badiali M; Moi L; Bianco G; Cacchione A; Locatelli F; Ferretti E; Mastronuzzi A
J Transl Med; 2014 Dec; 12():356. PubMed ID: 25524464
[TBL] [Abstract][Full Text] [Related]
19. NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
Tucker H; Umeweni N; Robertson J; Adam J
Lancet Oncol; 2014 Dec; 15(13):1425-1426. PubMed ID: 25499274
[No Abstract] [Full Text] [Related]
20. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]